Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Dobrosloveni – page 20

328 clinical trials in Dobrosloveni, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Dobrosloveni at a glance
328
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

328 trials in Dobrosloveni

Open in trial search

Study Comparing Sacituzumab Govitecan to Physician's Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Chronic hepatitis B

Not recruiting

Study of tenofovir disoproxil versus placebo for children aged 2-12 years with chronic hepatitis B infection

Registered drug
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Tenofovir Disoproxil
  • Sponsor:Gilead Sciences Inc.

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:pharmaand GmbH

Myelofibrosis+1

Not recruiting

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Kartos Therapeutics Inc.

Major depression+1

Not recruiting

Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Renal cell carcinoma

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Advanced Kidney Cancer and Intermediate or Poor Risk Factors

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:AstraZeneca AB

Study on Preventing Infections After Abdominal Surgery Using D-PLEX with Doxycycline Hyclate for Patients Undergoing Abdominal Surgery

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Doxycycline Hyclate
  • Sponsor:Polypid Ltd.

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study on JTT-861 for Patients with Heart Failure with Reduced Ejection Fraction

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:JTT-861 monohydrochloride dihydrate
  • Sponsor:Akros Pharma Inc.

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Dobrosloveni

What the registry says about research in the country

01 Cardiovascular Disease Trials

Clinical research in Dobrosloveni concentrates on Cardiovascular Diseases, with a primary focus on Atrial Fibrillation. The studies aim to evaluate innovative treatments that could reduce stroke, systemic embolism, and major bleeding risks.

  • Evaluation of the novel anticoagulant REGN7508 compared with standard therapy
  • Assessment of combined agents REGN7508 and REGN9933 versus placebo
  • Investigation of major bleeding outcomes in atrial fibrillation patients
  • Exploration of options for individuals unsuitable for oral anticoagulation

The single research site, supported by one investigator, is actively recruiting participants to generate safer and more effective strategies for preventing stroke and systemic embolism in the local community.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.